Skip to main content

Table 1 Treatment sequence regimens

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Treatment sequence Period 1 Interval between dosing Period 2 Interval between dosing Period 3
3 Days 2 to 15 days 3 days 2 to 15 days 3 days
1 A Continue metformin only C Stop all trial medications B
2 C Continue metformin only A Stop all trial medications B
  1. Treatment A (MET BID): Metformin IR 500 mg every 12 hours. Treatment B (RE BID): Remogliflozin etabonate 500 mg every 12 hours. Treatment C (MET + RE BID): Metformin IR 500 mg every 12 hours + remogliflozin etabonate 500 mg every 12 hours. Metformin was administered starting from the morning of Day 1 of Period 1 and stopped after the morning dose on Day 3 of Period 2. For any Treatment Period when remogliflozin etabonate was administered, remogliflozin etabonate dosing was stopped after the morning dose was given on Day 3.